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Abstract
Creutzfeldt-Jakob disease (CJD) is a rare prion disorder that has been the
subject of both professional and public interest following the identification of
variant CJD as a zoonotic disorder. There have been recent advances in
diagnostic techniques, including real-time quaking-induced conversion and
magnetic resonance imaging brain scan, that have allowed more accurate case
recognition in all forms of CJD. Although the epidemic of variant CJD is clearly
in decline, prevalence studies suggest that it may be premature to be
complacent about concerns for public health.
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Introduction
Creutzfeldt-Jakob disease (CJD) belongs to a family of fatal 
degenerative disorders of the nervous system known as trans-
missible spongiform encephalopathies or prion diseases, which 
affect both animals and humans1. The term prion, derived from 
proteinaceous infectious particle, was coined by Stanley Prusiner 
after the identification of the disease-associated protein2. The 
normal prion protein, PrPC, is present in all mammalian species 
and is encoded by the prion gene (PRNP) on human chromo-
some 20. The function of prion protein has not been established. 
Prion diseases are characterised by the deposition of PrPSc, an 
abnormally misfolded isoform of the native prion protein, within 
the nervous system. The mechanism for triggering this con-
formational change is not known, but the accumulation of this 
abnormal prion protein leads to neuronal degeneration, astrocytic 
gliosis, and spongiform change, resulting in a uniformly fatal 
neurological disorder3.
The human prion disorders are heterogeneous with different 
phenotypes, epidemiology, and pathogenesis. Sporadic CJD (sCJD) 
is the commonest human prion disease, accounting for around 
85% of cases; 10–15% are associated with mutations of PRNP 
and 1% are iatrogenic, most frequently associated with prior treat-
ment with human pituitary-derived hormones or human dura mater 
grafts. Variant CJD (vCJD) is a novel human prion disease 
which occurs predominantly in the UK and has been linked to the 
consumption of beef products contaminated with the agent of the 
cattle disease, bovine spongiform encephalopathy (BSE)4–6.
sCJD has a very rapid disease course; mean survival is six months. 
Indeed, over 90% of patients die within a year of symptom 
onset. The peak incidence is in the seventh decade, and younger 
(20–40s) or older (>80) cases are less common7. The favoured 
hypothesis is that sCJD is a spontaneous neurodegenerative 
disease, resulting from either a somatic PRNP gene mutation 
or a random structural change in the PrP protein causing the for-
mation of PrPSc2. An environmental source for the disease is not 
supported by epidemiological studies.
There have been recent developments in diagnostic investiga-
tions in CJD, and, although the vCJD outbreak is in decline, there 
are continuing concerns for public health in relation to the preva-
lence of infection in the normal population. These issues and the 
potential relevance of prion diseases to other neurodegenerative 
disorders are the main topics of this article.
Diagnosis
There is considerable variability in the way in which CJD can 
present clinically, which can make the initial diagnosis difficult. 
This heterogeneity of clinical presentation is linked, at least in part, 
to variations in the genotype at codon 129 of the prion protein gene 
and the type of PrPSc deposited in the brain. The genotype at codon 
129 can be methionine homozygous (MM), valine homozygous 
(VV), or heterozygous (MV), and in the UK population, the normal 
codon 129 distribution has been reported as 39% MM, 50% MV, 
and 11% VV8. Two biochemically distinct forms of PrPSc, type 1 
and type 2, can be deposited in the brain.
The classic clinical features of sCJD are rapid cognitive decline, 
ataxia, and myoclonus terminating in an akinetic mute state. The 
diagnosis of CJD is dependent upon assessment of clinical features 
together with specialist investigations. There has been an evolution 
in the diagnosis of CJD in recent years with the identification of new 
diagnostic tests, and this has been reflected in changes to the formal 
diagnostic criteria for sCJD used in the European Union (EU).
Magnetic resonance imaging
Magnetic resonance imaging in sporadic Creutzfeldt-Jakob 
disease. Magnetic resonance imaging (MRI) is the most useful 
investigation in sCJD, as it is highly sensitive and specific as 
well as widely available and relatively non-invasive9. The classic 
MRI findings in sCJD, including high signal in the caudate, 
putamen, or cortex (or a combination of these) on diffusion-
weighted imaging (DWI) and fluid-attenuated inversion recovery 
(FLAIR) sequences, are present in about 80% of cases9. DWI is 
more sensitive at detecting early cortical and subcortical changes 
(Figure 1).
Magnetic resonance imaging in variant Creutzfeldt-Jakob 
disease. Symmetrical hyperintensity in the posterior thala-
mus, relative to the anterior putamen, on T2-weighted or FLAIR 
MRI is characteristic of vCJD and is known as the pulvinar sign 
(Figure 2)10. This finding is very rare in other types of prion 
Figure 1. Magnetic resonance imaging of sporadic Creutzfeldt-
Jakob disease. Diffusion-weighted image at the level of the basal 
ganglia demonstrates marked symmetrical hyperintensity in the 
caudate head and putamen with less marked affection of the thalami. 
Image courtesy of David Summers, Western General Hospital, 
Edinburgh, UK.
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PrPSc, causing a change in the thioflavin T emission spectrum and 
enabling the reaction to be monitored in real time (Figure 3). It is 
also a useful investigation for some genetic forms of CJD15.
Real-time quaking-induced conversion olfactory mucosa and 
cerebrospinal fluid. The use of olfactory mucosa (OM) nasal 
brushings combined with RT-QuIC has been shown to improve 
the diagnosis of sCJD16. In a recent study17, the combined utilisa-
tion of CSF and OM RT-QuIC produced an overall specificity and 
sensitivity of 100% for the diagnosis of sCJD. OM RT-QuIC is 
limited, however, by the technical expertise required to obtain 
appropriate specimens. Although RT-QuIC is clearly a useful test 
for sCJD, the assay in its current form does not amplify the PrPSc 
in vCJD18.
Blood and urine tests in variant Creutzfeldt-Jakob disease
In an attempt to develop a better pre-mortem test for vCJD, a 
number of studies have attempted to detect the abnormal PrPSc 
in vCJD in blood and urine by using protein misfolding cyclic 
amplification (PMCA). In 2014, Moda et al. successfully detected 
PrPSc in the urine of patients with vCJD19. The study looked at 
238 urine samples from patients with vCJD, sCJD, or genetic prion 
diseases and healthy controls in a blinded study. Using PMCA, 
they were able to amplify the PrPSc to detectable amounts with 
a sensitivity of 93% and a specificity of 100% in vCJD. All the 
sCJD and control samples were negative.
Similar studies using PMCA have led to the detection of PrPSc in 
plasma from clinical vCJD as well as in pre-clinical blood sam-
ples taken from two vCJD patients who had donated blood prior 
to the onset of symptoms20,21. This is the first time that a test has 
successfully identified PrPSc in pre-clinical samples, and it may 
have the potential to be applied as a screening tool in transfusion 
medicine, although further validation is necessary.
Electroencephalogram
The electroencephalogram (EEG) is now a less useful inves-
tigation given the advent of MRI and CSF tests. Nonetheless, it 
remains an important, non-invasive surrogate marker for sCJD. 
The typical EEG appearances in sCJD are periodic, triphasic sharp 
wave complexes. These changes in the right clinical setting 
have a 90% specificity for CJD9 but are known to occur in other 
conditions, such as end-stage Alzheimer’s disease, Lewy body 
dementia, and metabolic encephalopathies22,23.
Diagnostic criteria for sCJD
The current diagnostic criteria used in the EU have been updated 
to include the cortical changes on MRI and RT-QuIC and are 
shown in Table 1.
Epidemiology
The incidence of sCJD is frequently quoted as one per million 
population per annum. However, there has been a consistent 
gradual increase in mortality rates in the UK and in many other 
countries in which systematic surveillance is undertaken. This 
may relate to changes in population demographics, with an 
increase in the numbers of individuals in the age cohorts with a 
disease11 and is reported to have a sensitivity of 78–90% and a 
specificity of 100% for vCJD in the right clinical setting5. The 
mediodorsal thalamic nucleus may also be involved and in com-
bination with pulvinar hyperintensity produces an appearance 
coined the ‘hockey stick sign’. In 86 neuropathologically con-
firmed cases, involvement of the caudate nucleus on FLAIR MRI 
was shown in 40%, the putamen in 23.3%, and the periaqueductal 
grey matter in 83.3% (Figure 2)10.
Until recently, all definite cases of vCJD have been MM at 
codon 129, which may account for the observed similarity of 
MRI findings in these cases when compared with other human 
prion diseases. This concept has been challenged, however, with 
the recent description of a neuropathologically confirmed case of 
vCJD with a heterozygous genotype at codon 12912. The MRI 
findings in this case demonstrated restricted diffusion in the basal 
ganglia, hypothalamus, insular cortexes, and medial thalami but 
not in the pulvinar nuclei.
Real-time quaking-induced conversion
A number of cerebrospinal fluid (CSF) biomarkers, including 
14-3-3, S100b, and tau, have been found to be elevated in patients 
with CJD. These proteins have limited specificity but can be 
diagnostically useful in the appropriate clinical context13.
Real-time quaking-induced conversion (RT-QuIC) is a relatively 
new CSF test which has shown remarkably high sensitivity and 
specificity in recent studies (sensitivity of 85.7% and specificity 
of 100%) in sCJD14. The technique involves using recombinant 
PrP as a substrate which is then induced to aggregate by adding 
CSF containing PrPSc. Thioflavin T then binds to the aggregated 
Figure 2. Pulvinar sign of variant Creutzfeldt-Jakob disease. 
Axial fluid-attenuated inversion recovery image demonstrates 
symmetrical hyperintensity of the posterior thalamic nuclei. Image 
courtesy of David Summers, Western General Hospital, Edinburgh, 
UK.
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Table 1. Diagnostic criteria for surveillance of sporadic Creutzfeldt-Jakob disease from 1 January 2017.
1.1     DEFINITE: 
                    Progressive neurological syndrome AND 
                    Neuropathologically or immunohistochemically or biochemically confirmed
1.2     PROBABLE: 
                    1.2.1     I + two of II and typical electroencephalograma 
          OR     1.2.2     I + two of II and typical magnetic resonance imaging brain scanb 
          OR     1.2.3     I + two of II and positive cerebrospinal fluid (CSF) 14-3-3 
          OR     1.2.4     Progressive neurological syndrome and positive real-time quaking-induced conversion in CSF or other tissues
1.3     POSSIBLE: 
                     I + two of II + duration <2 years
I         Rapidly progressive cognitive impairment
II        A    Myoclonus 
          B    Visual or cerebellar problems 
          C    Pyramidal or extrapyramidal features 
          D    Akinetic mutism
aGeneralised periodic complexes. bHigh signal in caudate/putamen on magnetic resonance imaging brain scan or at least two cortical regions 
(temporal, parietal, occipital) on either diffusion-weighted imaging or fluid-attenuated inversion recovery.
Figure 3. Real-time quaking-induced conversion (RT-QuIC) responses from reactions seeded with cerebrospinal fluid (CSF) from 
two sporadic Creutzfeldt-Jakob disease (sCJD) cases and a positive sCJD CSF control. The RT-QuIC from an unseeded reaction and a 
reaction seeded with brain homogenate from Alzheimer’s disease are also shown. Image courtesy of Neil McKenzie, University of Edinburgh, 
Edinburgh, UK. AD BH, Alzheimer’s disease brain homogenate; RFU, relative fluorescence units; ThT, thioflavin T.
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high incidence of sCJD, and improved case ascertainment as a 
result of increased awareness and more sensitive diagnostic inves-
tigations. Mortality rates of 1.5–2 cases per million may be more 
realistic on current evidence.
The vCJD epidemic is in marked decline both in the UK and 
internationally (Figure 4). Until recently, all tested cases of 
definite and probable vCJD had been MM at codon 129 of 
PRNP, but in 2015 a confirmed case with an MV genotype was 
identified12. This raises the possibility of a further outbreak, 
although it is likely that should this occur the number of cases will 
be relatively limited and probably lower than those of the primary 
epidemic in the MM population. The UK population were exposed 
to a significant level of BSE infectivity in the food chain in the 
1980s and early 1990s, and the relatively small scale of the vCJD 
epidemic may imply a significant barrier to infection between 
bovines and humans24.
Secondary transmission of vCJD through blood transfusion is 
now established with three clinical cases of vCJD linked to the 
transfusion of non-leucodepleted red blood cells derived from 
individuals who themselves went on to develop vCJD25. In 
addition, a recipient of an implicated transfusion who died of a 
non-neurological disorder was found to have PrPSc positivity in 
the spleen, suggesting pre-clinical infection26. This individual was 
a codon 129 heterozygote, and laboratory transmission studies 
demonstrated prion infectivity in the spleen with characteristics 
similar to those of primary cases.
The prevalence of vCJD infection in the general UK population 
has been studied by examining routine appendicectomy samples 
by immunocytochemistry. Positive samples were identified in 
19 out of 33,115 appendices, leading to an estimated prevalence 
of 1 in 4,000 in the general population27. This is a matter of 
concern, as there is no clinical evidence of infection prior to 
neuro-invasion in prion diseases and the mean incubation period 
in vCJD has been estimated to be 15 years. A more recent study 
examined appendix samples from before 1980, prior to the 
presumed start of the BSE epidemic, and in those born after 1996, 
after which human exposure to BSE was thought to be minimal. 
Surprisingly, 7 out of 15,959 of these samples were positive, 
suggesting either a more extended period of human exposure to 
BSE or perhaps that positivity may not imply infection with vCJD28.
Other misfolding protein disorders
In addition to prion diseases, there are a number of diseases 
associated with protein misfolding. These conditions are 
associated with the accumulation of oligomers of A-beta, 
tau, and alpha-synuclein and include Alzheimer’s disease, 
Parkinson’s disease (PD), and Huntington’s29. The identification of 
Figure 4. Variant Creutzfeldt-Jakob disease cases by year and country. MV, methionine valine heterozygous; PRNP, prion gene.
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alpha-synuclein deposits in a foetal graft in patients with PD30,31 led 
to the hypothesis that there may be the potential of seeding of 
protein from abnormal to normal tissue and subsequently there 
have been extensive studies in laboratory animals that suggest 
that this may occur in many protein misfolding disorders32. The 
presence of beta-amyloid deposits in the brains of human growth 
hormone recipients and not in age-matched controls has added 
to concerns about parallels between prion diseases and other 
neurodegenerative diseases33,34. Whether this is an important 
issue for public health is uncertain and there may be a differ-
ence between seeding of protein and the actual transmission of a 
disease. One epidemiological study, for example, has shown no 
evidence of transfusion transmission of a number of neurodegen-
erative disorders, including Alzheimer’s disease35.
Conclusions
The diagnosis of CJD has improved in recent years with the 
advent of improved brain imaging and the development of spe-
cific CSF tests in sCJD and the potential for diagnostic tests in 
plasma and urine in vCJD. The public health concerns raised by 
the BSE epidemic have clearly decreased as new cases of vCJD 
have become a rarity in both the UK and other countries. 
However, the potential prevalence of infection in the general 
population remains a matter of concern and the parallels between 
prion diseases and other protein misfolding disorders are an area of 
active and continued research.
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